PDEδ/NAMPT IN-1

PDEδ/NAMPT IN-1 (Compound 17d) is a dual inhibitor targeting phosphodiesterase 6 (PDE6) (KD=0.410 nM) and nicotinamide phosphoribosyl transferase (NAMPT) (IC50=2.21 nM) . PDEδ/NAMPT IN-1 blocks KRAS-related signal transduction and interferes with the synthesis of nicotinamide adenine dinucleotide (NAD+), inducing apoptosis in KRAS mutant pancreatic cancer cells. PDEδ/NAMPT IN-1 is promising for research of KRAS mutant pancreatic cancer[1].

Product Specifications

CAS Number

[2976498-55-0]

UNSPSC

12352211

Target

Apoptosis; NAMPT; Phosphodiesterase (PDE)

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=S(C1=CC=C(C=C1)NC(NCC2=CC=CN=C2)=O)(N(CC3=CC=C(C=C3)OC)C4CCCC4)=O

Molecular Formula

C26H30N4O4S

Molecular Weight

494.61

References & Citations

[1]Zhu Y, et al. Discovery of Potent PDEδ/NAMPT Dual Inhibitors: Preclinical Evaluation in KRAS Mutant Pancreatic Cancer Cells. J Med Chem. 2025 May 8;68 (9) :9241-9259.